explore -WSS

explore

author：knowledge 2025-08-26 10:55:30 - browse：77433

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： J&J to buy cancer drug developer Ambrx Biopharma

hotspot

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Feng Zhang, Grail founder join forces on new gene editing startup

UCB departs biotech trade group BIO

How to fix the rural physician shortage in the U.S.

In search for therapies for solid tumors, companies turn to claudin

focus

explore

leisure time

Jerome Adams on the need for new antivirals for Covid

RSV vaccines may be linked to small increased risk of developing GBS

Sports medicine is finally prioritizing gender equality

Burning questions for the 2024 JPM Healthcare Conference

Dobbs anniversary: the lost opportunity of abortion as health care

Why getting cancer drugs just got harder for rural patients

How to save PrEP access — and even expand it

In search for therapies for solid tumors, companies turn to claudin

At least 13 dead in Texas as scorching temps continue

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Wikipedia

Change Healthcare cyberattack outage could last weeks

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Covid isolation guidance eased by the CDC

Biotech companies concerned about China biosecurity crackdown

Burning questions for the 2024 JPM Healthcare Conference

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

focus

entertainment

hotspot

knowledge